Allurion, a Boston-based startup offering a non-invasive gastric balloon by swallowing a pill, has gained $27 million in Series C funding from previous investor Romulus Capital, with new participation from Cogepa Investments and IDO Investments, an innovation firm based in Oman. Read More
Allurion, a Boston-based startup offering a non-invasive gastric balloon by swallowing a pill, has gained $27 million in Series C funding from previous investor Romulus Capital, with new participation from Cogepa Investments and IDO Investments, an innovation firm based in Oman. 
Post a Comment for "Gastric bypass surgery in a pill startup Allurion gets $27 million as it pursues FDA approval"